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Introduction
Deleted in liver cancer 1 (DLC1) was identified as a putative tumor suppressor in hepatocellular carcinoma (HCC) in 1998 1 . Since its identification, accumulating evidence has shown that DLC1 is not only involved in HCC, but also in diverse human cancers 2 . DLC1 is a focal adhesion protein and functions as a Rho GTPase activating protein (RhoGAP) 3 .
Localization at focal adhesions, interaction with tensin proteins and RhoGAP activity are crucial to the tumor suppressor functions of DLC1 [4] [5] [6] [7] [8] . When ectopically expressed in cancer cells, DLC1 inhibits proliferation and induces apoptosis 7, [9] [10] [11] [12] . Furthermore, DLC1 abrogates cell motility and functions as a suppressor of metastasis in cancer cells 7, [13] [14] [15] . Conversely, depletion of DLC1 in cells enhances growth and motility potential 16, 17 . Functional data about the loss of DLC1 in HCC tumorigenesis using a knockdown approach was recently demonstrated in a mouse model 18 .
DLC1 is widely expressed in normal human tissues, but it is frequently underexpressed in HCC and other cancers. Heterozygous deletion and promoter hypermethylation of DLC1 are commonly found in about 30-50% of prostate 19 , breast 20 and liver cancers 21, 22 . Other mechanisms could possibly be involved in the regulation of DLC1 activity in tumor tissues with normal expression of DLC1. Indeed, somatic mutations of DLC1 have been recently detected in human prostate cancers 23 . These mutations localize in the focal adhesion targeting region and impair the RhoGAP activity of DLC1. Although DLC1 expression has been well documented to be regulated at the transcriptional level, a recent study about regulation of the activity and compartmentalization of DLC1 by protein kinases has provided evidence that DLC1 activity could be regulated by post-translational modification. Activated protein kinase C (PKC) and protein kinase D (PKD) stimulate the association between DLC1 and 14-3-3
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proteins. Enhanced association blocks DLC1 nucleocytoplasmic shuttling and inhibits the RhoGAP activity of DLC1 24 . Moreover, identification of the rat homolog of DLC1, p122RhoGAP, as a substrate of Akt has provided insights into a potential regulatory pathway of DLC1 25 . However, the functional significance Akt phosphorylation of p122RhoGAP and its relevance to human DLC1 have not been investigated. The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is an important cell survival cascade. An aberrant Akt signaling pathway and downstream effectors have been shown to have crucial roles in human cancers 26 . Here, we hypothesized that Akt is involved in the regulation of the tumor suppression activity of DLC1 in HCC. In this study, we elucidated the molecular mechanism of Akt phosphorylation of DLC1 in liver cancer cells and determined the functional significance of hyperphosphorylated DLC1 in oncogenically transduced mouse hepatoblasts.
Materials and Methods
Constructs and reagents
Expression constructs of Myc-tagged wild-type DLC1 (1-1091), deletion mutants (1-292, 1-595, 1-807, 292-1091, 648-1091, ∆414-432), the RhoGAP mutant (K714E) and GFP-tagged DLC2α were constructed as previously described 7, 8, 27 . DLC1 internal deletion mutants (∆292-353, ∆292-646, ∆375-509 and ∆414-432), phospho-defective mutants (S298A, S329A, S432A and S567A) and the phosphomimetic mutant (S567D) as well as wild-type DLC2α and the DLC2α phospho-defective mutant (S589A) were generated. Wild-type DLC1, S567A and S567D fragments were subcloned into the MSCV-PGK-PIG vector harboring a 6×Myc tag at the N-terminus 18 . The full-length Akt1 fragment was amplified from normal human liver cDNA. A PCR-based site-directed mutagenesis method was used to generate the constitutively active mutant (E17K) 28 , the kinase dead mutant (K179M) and the phospho-defective mutant (AA, T308AS473A). Amplified fragments were cloned into pCS+MT and FLAG-pcDNA3. LY294002 was from Calbiochem (San Diego, CA) and insulin was from Novo Nordisk (Denmark).
Cell culture
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The human embryonic kidney cell line, HEK293T, and hepatocellular adenoma cells, 
Colony formation assay
SMMC-7721 cells were seeded at 1×10 5 per well into 12-well tissue culture plates. One of the DLC1 expression vectors (pCS2+MT, DLC1-pCS2+MT, DLC1S567A-pCS2+MT or DLC1S567D-pCS2+MT) was co-transfected with 0.2 μg of pcDNA3.1+(neo) into cells. Cells were trypsinized and replated in a 1:20 dilution in triplicates one day after transfection. Cells were selected in 700 μg/ml of G418 (Merck, Darmstadt, Germany) for three weeks. Colonies formed were fixed with 3.7% formaldehyde and stained with crystal violet solution.
Subcutaneous injection and orthotopic liver implantation in nude mice
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In vivo tumorigenicity of mouse hepatoma p53 
Protein extraction, co-immunoprecipitation and western blotting
Experimental details of protein lysis, co-immunoprecipitation and western blotting have been previously described 27 . Ectopically expressed epitope-tagged proteins were
A C C E P T E D M A N U S C R I P T immunoprecipitated from total cell lysates using antibodies against the tagged epitope, and the endogenous DLC1 protein was immunoprecipitated by an anti-DLC1 antibody.
Immunoprecipitated proteins were subjected to western blotting, and phosphorylation signals were determined using the PAS antibody (Cell Signaling).
In vitro kinase assay
The in vitro kinase assay was performed using an Akt kinase assay kit (Cell Signaling Technology) according to the manufacturer's manual with slight modifications. Recombinant GST-DLC1 protein was generated by a GST expression system. GST-DLC1 or 
Statistical analysis
Student's t-test analysis by GraphPad Prism 5.02 (San Diego, California, USA) was used to determine the difference between the results of experimental groups with those of the control.
A P-value less than 0.05 was regarded as statistically significant. Mean and standard deviation (s.d.) of each group were calculated and shown.
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Results
DLC1 is a substrate of Akt
ScanProsite protein sequence analysis of DLC1 revealed the presence of three characteristic phospho-Akt substrate (PAS) motifs, (R/K)XRXX(S*/T*) (R: arginine; K:
lysine; S* and T*: phosphorylated serine and threonine; and X: any amino acid) at amino acids 293-298 (RKRSVS*), 324-329 (RTRSLS*) and 562-567 (RLRWHS*) of DLC1 ( Figure   1A ). Three potential Akt phosphorylation serine residues, S298, S329 and S567, are all localized in the central region of DLC1 and are conserved among human DLC1 and rat p122RhoGAP. S329 corresponds to S322 of the rat homolog, which was previously reported to be phosphorylated by Akt 25 . To elucidate whether Akt also phosphorylates human DLC1,
we employed an antibody against PAS to detect the phosphorylation of DLC1. The 
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Akt phosphorylates DLC1 at S567
To identify the Akt-phosphorylated residue(s) in DLC1, a panel of DLC1 deletion mutants was examined for the phosphorylation signal ( Figure 2A ). Loss of the PAS signal in the ∆292-646 mutant suggested that the phosphorylated residue(s) was located in amino acids 292-646 of DLC1 ( Figure 2B ). Detection of the signal in the ∆292-353 mutant, in which S298
and S329 were removed, implicated that S567 was the potential Akt-phosphorylated residue.
In addition, detection of signal in the 400-1091, 450-1091 and 500-1091 mutants but not in the 648-1091 mutant further supported that S567 was the phosphorylation target (Supplementary Figure 3) . Intriguingly, the PAS signal could not be detected in C-terminal deletion mutants, such as 1-595, 1-807, 1-878, 1-989, suggesting that an intact START domain is required for phosphorylation of DLC1 by Akt ( Figure 2C ; Supplementary Figure   3B ). However, the functional significance of the START domain in Akt phosphorylation of DLC1 remains to be further investigated. Direct phosphorylation of DLC1 by Akt was confirmed by the in vitro kinase assay using recombinant Akt1 and GST-DLC1 500-1091 and 500-878 fusion proteins ( Figure 2D ).
In order to validate that S567 is the target of Akt phosphorylation, phospho-defective mutants (S298A, S329A, S567A) with an alanine substitution of S298, S329 and S567, respectively, were created ( Figure 2A ). The phosphorylation was completely absent in the S567A mutant, whereas a strong signal was detected in wild-type DLC1 as well as in both S298A and S329A mutants ( Figure 2E ). In addition, co-transfection with Akt dramatically enhanced the phosphorylation in all DLC1 constructs, with the exception of S567A.
Consistently, recombinant Akt1 strongly phosphorylated immunoprecipitated Myc-tagged DLC1, S298A and S329A, but not S567A ( Figure 2F ).
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Akt phosphorylates DLC2 at the corresponding residue to DLC1 S567 DLC family members (DLC1, DLC2 and DLC3) are structurally conserved with high sequence homology 30 ( Figure 3A ). Sequence analysis also revealed the presence of putative PAS motifs in amino acids 253-258 (RARAKS*), 567-572 (RDRRDS*) and 584-589
(RLRWHS*) of DLC2 and in amino acids 203-208 (RHRNRS*), 556-561 (RERRDS*) and 563-578 (KLRWHS*) of DLC3. Among all putative PAS motifs, S567 of DLC1 is the only putative phosphorylation residue to be conserved in the family. S567 of DLC1 corresponds to S589 of DLC2 and S578 of DLC3 ( Figure 3A) . We found that the phosphorylation was also detected in DLC2 and was enhanced when DLC2 was co-transfected with Akt ( Figure 3B ).
Substitution of S589 with alanine completely abolished the phosphorylation and suggests that
Akt phosphorylates DLC2 at the corresponding S589.
DLC1 interacts with Akt
Demonstration of Akt phosphorylation of DLC1 prompted us to further investigate whether DLC1 interacts with Akt. Co-immunoprecipitation confirmed interaction between ectopically expressed DLC1 and Akt ( Figure 4A ). Apart from wild-type Akt, only the constitutively active Akt E17K mutant could robustly interact with DLC1, but the kinase dead Akt, K179M, and phospho-defective, T308AS473A (AA), mutant failed to associate with DLC1. This result revealed the requirement of Akt kinase activity in DLC1-Akt association.
In accordance with this finding, DLC1 was only phosphorylated by wild-type and constitutively active Akt. Endogenous Akt was shown to interact with Myc-DLC1, and the interaction of these proteins was enhanced upon insulin stimulation ( Figure 4B ). We also questioned whether the phosphorylation status of DLC1 would affect its interaction with Akt.
Our result showed that S567A had largely reduced interaction whereas S567D displayed a stronger binding with Akt compared to the wild-type DLC1 ( Figure 4C ). This suggests that ACCEPTED MANUSCRIPT
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S567 phosphorylation status of DLC1 correlates to its binding with Akt. Another serine residue, S432, resides in a pseudo-site with a sequence (KRRNSS*) similar to the consensus PAS motif. Substitution of S432 with alanine also did not affect the DLC1-Akt interaction, and this further supports the idea that the DLC1-Akt interaction is specifically determined by phosphorylation at S567 ( Figure 4D ).
Akt phosphorylation of DLC1 regulates its growth suppression activity
DLC1 has been well documented to inhibit cell growth when ectopically expressed in various cancer cell lines 7, 23, 31, 32 . To determine the functional significance of phosphorylation of DLC1 at S567, we performed a colony formation assay using SMMC-7721 cells to compare the growth suppression activities of DLC1 with its mutants ( Figure 5A ). The S567A mutant inhibited colony formation as efficiently as wild-type DLC1. Both the RhoGAP mutant K714E and the phosphomimetic mutant S567D lost the ability to inhibit colony formation. The growth suppression activity of DLC1 was also assessed by colony formation assays and proliferation curves in an activated Akt background. These assays revealed that wild-type DLC1 lost growth inhibitory activity, whereas the S567A mutant retained its ability to suppress HCC cell growth (Supplementary Figure 4) . Our findings implicate that phosphorylation at S567 by Akt deregulates the activity of DLC1 in suppressing cell growth.
Recently, functional data about the loss of DLC1 in HCC tumorigenesis using specific short-hairpin RNA interference were first demonstrated in a mouse model 18 . To determine the physiological relevance of DLC1 phosphorylation in tumorigenicity, we stably expressed DLC1 and its mutants in a mouse p53-null hepatoblast cell line expressing an oncogenic Ras and S567A dramatically suppressed cell growth ( Figure 5C ) and anchorage-independent
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A C C E P T E D M A N U S C R I P T growth ( Figure 5D ). In contrast, S567D displayed largely attenuated growth suppression activity when compared to DLC1 and S567A. S567D cells grew faster and formed more and bigger colonies. DLC1 has been shown to induce apoptosis in an HCC cell line 12 . To investigate whether Akt phosphorylation affects the apoptosis-inducing activity of DLC1, stable clones of DLC1 were subjected to flow cytometry and TUNEL staining (Supplementary Figure 5) . The data showed a higher percentage of subG1 population and more positive TUNEL-stained cells were detected in DLC1 and S567A cells when compared with the control and S567D cells. Moreover, wildtype DLC1 was shown to lose its ability to induce apoptosis in hepatoma cells with activated Akt background. The stable clones of DLC1
and its mutants were then injected subcutaneously into nude mice and tested for their in vivo tumorigenicity ( Figure 5E ). Both wild-type DLC1 and the S567A mutant efficiently suppressed tumor formation, whereas S567D mutant formed the biggest tumors among all experimental groups ( Figure 5F ).
Solid tumors excised from subcutaneous injection were subjected to orthotopic liver implantation. Three weeks after implantation, luciferase imaging revealed inhibition of tumor growth by wild-type DLC1 and the S567A mutant when compared to the control. In contrast, the S567D mutant accelerated tumor growth ( Figure 6A ). In accordance with the luciferase signal, wild-type DLC1 and the S567A mutant formed smaller tumors whereas S567D formed the largest tumors among all groups ( Figure 6B ). Wild-type DLC1 and the S567A mutant delayed tumor onset in vivo. Because of the enormous tumor formation, animals of S567D group were the first to die ( Figure 6C ). Examination of the livers revealed that tumor microsatellite formation was found in two out of four mice from the S567D group in contrast to only a single focus of microsatellite formation found in just one mouse each in the vector and wild-type groups ( Figure 6D and 6F). Distant metastases in the lungs were found in all ACCEPTED MANUSCRIPT
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mice from the S567D group and in none of the mice in the wild-type group ( Figure 6E and   6F ). In the S567D group, large foci of lung metastasis were found in three mice, and a total of 10 large foci were observed. Although lung metastases were found in two mice in each of the vector and S567A groups, large foci were found in two mice, and a total of 12 foci were formed in the vector group. However, in two mice of the S567A group, mostly micrometastases were observed, and only two large foci were found in the whole group.
Collectively, the incidence of lung metastases and aggressive features were reduced in tumors derived from the wild-type and S567A groups. Our data revealed that both wild-type and S567A mutant DLC1 efficiently suppressed the metastatic potentials of hepatoma cells but that the S567D mutant lost the inhibitory ability to suppress metastasis.
Discussion
In this study, we have shown that Akt is a novel regulator of DLC1. Activated Akt interacted with and phosphorylated DLC1 at S567. Hyper-phosphorylated DLC1 lost its tumor suppressive activity in tumorigenesis and metastasis ( Figure 7) . A previous study reported that Akt phosphorylates rat DLC1, p122RhoGAP, at S322 25 . However, our data showed that Akt did not phosphorylate S329 (which corresponds to S322 of p122RhoGAP), but that instead, S567 is the major target of Akt. This reflects differential regulatory signaling pathways in rat and human DLC1 or in different cell types. In spite of the differential regulation between orthologs, our data showed that Akt also phosphorylated the corresponding residue in another human DLC family member, DLC2. Although we did not provide evidence about Akt phosphorylation of DLC3, conservation of S567 of DLC1 with the corresponding residues in DLC2 and DLC3 implies that DLC3 could also be ACCEPTED MANUSCRIPT
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phosphorylated by Akt. Our findings here have provided the first evidence about the importance of S567 and point to a common regulatory mechanism in the DLC family.
All DLC family members share a similar structural organization, including the presence of a sterile alpha motif (SAM) domain at the amino-terminus as well as RhoGAP and steroidogenic acute regulatory (StAR)-related lipid transfer (START) domains at the carboxyl-terminus. The central region between the SAM and RhoGAP domains is less conserved among family members and has no specialized structural domain 30 . Nevertheless, the central region has been shown to be responsible for focal adhesion localization and interaction with tensins, events which are crucial to the growth suppression activity 5, 6, 8, 27 .
The central region of DLC1 has been shown to be phosphorylated by PKC/PKD 24 .
Phosphorylation of DLC1 by PKC and PKD enhances its interaction with the 14-3-3 adaptor The present study has shown that phosphorylation of DLC1 at S567 by Akt reduced the ability of DLC1 to inhibit the cell growth of both human HCC cells in vitro and mouse hepatoblasts in vivo as well as the metastasis of the latter. The inhibitory function of DLC1 in cancer cell metastasis has been reported in breast cancer cells 13 . In this study, we demonstrated that DLC1 also functions as a negative regulator of mouse hepatoma metastasis.
In the physiological context, enhanced activation of Akt through phosphorylation at S473
in clinical HCC samples has been detected and correlated with poorer overall survival 33 . Apart from down-regulation of DLC1 expression observed in about 50% of cancers 21, 22 , enhanced phosphorylation levels of DLC1 could be an indicator for functionally deregulated DLC1 in
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cases with normal expression level of DLC1. Elevated expression levels and hyperactivation of Akt have been observed in many human cancers 34 , and DLC1 has been shown to be functionally involved in diverse human cancers. In this regard, deregulation of DLC1 tumor suppressor functions by enhanced activation of Akt is implicated in a broad spectrum of human cancers. In order to validate the altered Akt/DLC1 signaling pathway in human cancerous tissues, generation of specific phospho-DLC1 (S567) antibody will be an indispensable tool. Due to the failure in generating the phospho-DLC1 after several attempts, the study of the enhanced phosphorylation of DLC1 in human cancers cannot be accomplished at present and awaits investigation in future.
Focal adhesion localization and RhoGAP activity have been demonstrated to have crucial roles in the tumor suppression activity of DLC1 5, 6, 8, 11, 23, 35 . However, our data revealed that the focal adhesion localization and RhoGAP activity of DLC1 were not affected by phosphorylation by Akt. Immunofluorescence staining revealed that, similar to wild-type DLC1, both S567A and S567D mutants displayed punctate patterns at the boundary that perfectly co-localized with vinculin in SMMC-7721 cells (Supplementary Figure 6A) .
RhoGAP activity of DLC1 could be reflected by its ability to inhibit RhoA activity and stress fiber formation 7, 23, 35, 36 . Upon transient transfection, wild-type DLC1 inhibited serum-induced stress fiber formation in SMMC-7721 cells, but the K714E RhoGAP mutant lost the ability to suppress stress fiber formation (Supplementary Figure 6B) . Both S567A and S567D inhibited stress fiber formation as efficiently as wild-type DLC1. Consistently, a rhotekin pull-down assay showed that RhoA activity was inhibited in all stable HCC clones of wild-type and mutant DLC1 (Supplementary Figure 6C) . Collectively, in spite of the deregulation of DLC1 tumor suppression functions by Akt phosphorylation, the RhoGAP activity of DLC1 was not affected. Indeed, mediation of growth suppression activity via ACCEPTED MANUSCRIPT
RhoGAP-independent mechanisms has been implicated in non-small cell lung cancer (NSCLC) cells 15 . Expression of a GAP-deficient DLC1 mutant also inhibited anchorage-independent growth and invasion of NSCLC cells, although to a lesser extent than the wild-type DLC1 did. Abrogation of the tumor suppressive activity of DLC1 by Akt phosphorylation through a RhoGAP-independent pathway suggests that DLC1 is potentially involved in other, undefined mechanisms, which await further investigation. Stable cell lines were established under 1ug/ml puromycin selection for 1-2 weeks.
ACCEPTED MANUSCRIPT
Supplementary Materials and Methods
Colony
Proliferation curve
Cells were seeded at 1×10 4 cells per well of 12-well culture plates in triplicates and maintained in growth medium. Cell numbers were counted by using a hematocytometer at 24-hr intervals for 5 days. Mean values and standard deviations of the triplicates were calculated and plotted against time.
Flow cytometry
Mouse p53-/-; RasV12 and p53-/-; Akt hepatoma cells stably expressing DLC1 and its mutants were fixed with 0.5% paraformaldehyde in PBS and permeabilized with 70% ethanol.
Cells were then stained with propidium iodide and DNA profile of cell populations was determined by flow cytometry and analyzed by WINMDI version 2.9. Apoptotic cells were defined as cells in subG1 population. Percentage of cells in subG1 phase in each stable clone was determined. Data represent the mean of triplicates and standard deviation was calculated.
Terminal decxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay
Cells with at 1×10 4 were seeded on coverslip in 12-well culture plate and cultured for 2 days.
The cells on coverslip were fixed with 4% paraformaldehyde. TUNEL assay (in situ cell death detection kit, TMR red) was then performed according to the manufacturer's manual (Roche).
Immunofluorescence staining
To reveal the subcellular localization of Myc-and FLAG-DLC1 in SMMC-7721 cells, transfected cells were fixed with paraformaldehyde and permeabilized with Triton-X-100. 
Rhotekin pull down assay
The RhoA activity levels in DLC1 transiently transfected cells and in DLC1 stable hepatoma cells were detected using a Rho Activation Assay Biochem Kit (Cytoskeleton) as described elsewhere16. Cells were serum-starved for 24 hours and stimulated with lysophosphatidic 
